MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2016.
•First quarter 2016 revenue was $16.7 million, representing a 25% increase over the first quarter 2015.
• First quarter 2016 gross margin was 81% compared to 79% in the first quarter 2015.
•First quarter 2016 revenue was $16.7 million, representing a 25% increase over the first quarter 2015.
• First quarter 2016 gross margin was 81% compared to 79% in the first quarter 2015.
